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SUMMARY 
A total of 90 patients including 30 patients of generalized anxiety disorder and 30 of dysthymic disorder 
according to DSM III criteria plus 30 patients of mixed anxiety-depressive disorder were given a detailed psychiatric 
evaluation and four rating scales were made for measuring the level of anxiety and depression at intake and to record 
their improvement with treatment. Half the subjects in each group were randomly selected for treatment with 
imipramine and the other half with diazepam. Imipramine and diazepam were found to be equally effective (62.8% 
vs 62.2%) in reducing anxiety in all subjects. Imipramine was significantly better than diazepam in reducing the 
level of depression in the depressed group but as effective as diazepam in the other two groups. Imipramine was 
significantly better for the symptoms of 'depressed mood' and 'retardation', while diazepam was better in the 
symptom of 'fears'. None of the other symptoms was discriminatory. 
The nosological distinction between an-
xiety states and depressive neurosis has long 
been a subject of controversy, although the 
use of anxiolytics for the treatment of the-
former and antidepressants for the latter 
has been almost taken for granted. In clini-
cal practice patients presenting with symp-
toms of both anxiety and depression are a 
common experience and their labelling 
into one or other category is difficult and 
mostly arbitrary. Even in patients of anxiety 
neurosis, depressive mood can be seen both 
prior to the first anxiety attack or later in 
the course of the disorder and sometimes 
the anxiety neurosis even appears to take on 
a predominantly depressive character 
(Marks and Lader 1973). On the other 
hand, in patients suffering from a depres-
sive illness, diffuse anxiety or specific fears 
are almost always present to some extent 
(Hamilton 1980). This is supported by the 
recent reports of Akiskal (1984) who found 
that anxious depressions are the most com-
mon dysphoric mood state and such pa-
tients respond well to tricyclic antidepres-
sants. Earlier, the collaborative study on 
pharmacotherapy of anxiety and depression 
reported by Lipman et al. (1974) clearly 
showed that in highly anxious subjects, imi-
pramine produced a significant reduction 
of both anxiety and depression when com-
pared to chlordiazepoxide or placebo. 
These effects seemed to run parallel and 
there is strong evidence to suggest that the 
observed antianxiety effect of tricyclics is 
independant of their antidepressant effects 
(Tyrer 1973, Zitrin 1980, 1983, Sheehan 
1980) and more recently Leibowitz (1984) 
reported acute anxiety and panic attack 
were the best indicators of phenelzine re-
sponse in their cohort of anxious depres-
sives, although their utility in the treatment 
of generalized anxiety disorders appears li-
mited (Klein 1978). Long term followup 
studies such as those of Leckman et al. 
(1981) indicate that patients who have an 
anxiety disorder also have a high incidence 
of depression, this relationship being parti-
cularly strong for panic disorder and de-
pression. The effectiveness of anti-depres-
sants in the treatment of panic disorder 
(Tyrer 1973, Mountjoy and Roth 1977, 
McNair and Kahn 1981) and their relative 
ineffectiveness in the case of generalized 
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anxiety disorder has led some investigators 
to suggest that panic may be a form of aty-
pical depression and generalized anxiety 
disorder is actually a prodromal, incom-
plete or residual manifestation of other psy-
chiatric disorders lacking validity as a separ-
ate diagnostic entity. 
From the above it was evident that pan-
ic attacks, phobic anxiety and obsessive-
compulsive disorder are distinct entities 
and clinically, genetically and in their re-
sponse to anti-depressant drugs are distinct 
from the core 'generalized anxiety disor-
der'. Further, that almost all the earlier stu-
dies on anxiety states have included all 
types of patients under the broad category 
of 'Anxiety State' and it undoubtedly inf-
luenced the results of the studies. It was 
therefore decided to study the response to 
treatment of the pure generalized anxiety 
disorder to anxiolytic and anti-depressant 
drugs and compare them with a pure de-
pressive group and a mixed anxious-depres-
sive group. 
Aims 
1. To study the clinical signs and symptoms 
in three groups of patients diagnosed ac-
cording to DSM III criteria as: 
a) Generalised anxiety disorder -
Group A. 
b) Mixed anxiety-depressive disorder 
GroupM. 
c) Dysthymic disorder or depressive 
neurosis-Group D. 
2. To study the response to treatment with: 
a) a benzodiazepine anxiolytic-diaze-
pam. 
b) a tricyclic antidepressant-imipramine. 
Material and Methods 
Ninety consecutive patients presenting 
with symptoms of anxiety and/or depres-
sion in the psychiatry O.P.D. of Rajendra 
Hospital, Patiala were taken up for the stu-
dy. These patients were subdivided into 3 
groups of 30 patients each, as per the DSM 
III criteria mentioned above. 
Exclusion criteria - all patients with a 
primary diagnosis of any other psychiatric 
disorder including panic attacks, phobic 
and obsessive-compulsive neurosis, psycho-
sis, alcoholism or sociopathy and organic 
brain disorder. In addition, patients having 
anxiety or depressive symptoms secondary 
to other medical illness or drug intake were 
also excluded. 
Each patient was interviewed using a 
standardized history taking proforma, and 
then assessed on four instruments i.e. (1) 
Hamiltons rating scale for anxiety (2) Tay-
lors manifest anxiety scale (3) Hamilton 
rating scale for depression and (4) Amritsar 
depressive inventory. Thus we had two self 
rating scales to evaluate the subjective 
emotional state and the two Hamilton 
scales for objective assessments by the in-
terviewer. Half the subjects in each of the 
three groups were then randomly assigned 
either to treatment with imipramine or dia-
zepam. The dose was - imipramine 25 mg 
or diazepam 5 mg-one tablet three times a 
day in the first week and increased to 2 
tablets three times a day if adequate re-
sponse was not achieved. Duration of treat-
ment was 4 weeks. 
The statistical analysis of data was done 
by using: 
a) Chi test of significance. 
b) Analysis of variance by F test. 
Results 
Socio-Demographic Variables like age, sex, 
type of onset, precipitating factors and fam-
ily history of psychiatric illness are given 
below. All these groups are similar on all 
these variables, in all respects, there being 
no significant difference between the 
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Group A 
(N = 30) 
Group M 
(N = 30) 
Group D 
(N = 30) 
Age distribution. 
Less than 30 years 
30-40 years 
More than 40 years 
13 
6 
11 
15 
11 
4 
11 
8 
11 
X
2 = 5.64 
N.S. 
Sex distribution: 
Males 
Females 
12 
18 
17 
13 
18 
13 
X
2 = 2.76 
N.S. 
Type of onset: 
Sudden 
Gradual 
9 
21 
12 
18 
13 
17 
X
2 = 1.23 
N.S. 
Presence of precipitating factors: 
Present 
Absent 
6 
24 
10 
20 
10 
20 
X
2 - 5.42 
N.S. 
Family history of similar 
psychiatric illness: 
Present 
Absent 
4 
26 
12 
18 
10 
20 
X
2 = 5.61 
N.S. 
Table 1 
Response to treatment with imipramine and diazepam as measured on Hamilton Anxiety Scale 
Imipramine  Diazepam 
Initial 
score 
Final 
score 
Percent 
reduction 
Initial 
score 
Final 
score 
Percent 
reduction 
Group A 
Group M 
Group D 
19.5 
17.5 
10.8 
7.3 
7.5 
2.8 
62.5 
57.1 
73.4 
16.5 
19.7 
9.7 
4.9 
7.1 
3.8 
70.4 
63.9 
60.9 
Table 2 
Response to treatment with imipramine and diazepam as measured on Hamilton Depression Scale 
Imipramine  Diazepam 
Initial 
score 
Final 
score 
Percent 
reduction 
Initial 
score 
8.3 
20.0 
17.1 
Final 
score 
2.7 
8.7 
9.5 
Percent 
reduction 
58.5 
56.3 
44.1 
Group A 
Group M 
Group D 
12.0 
17.2 
18.5 
6.1 48.8 
6.9 66.5 
4.9 73.6 52  ANXIETY AND DEPRESSIVE NEUROSIS 
Response to treatment: 
Tables 1 & 2 show the mean, initial and 
final scores in the three diagnostic Groups 
A, M and D consisting of 30 patients each 
on the Hamilton Anxiety Scale, after treat-
ment with imipramine (N = 15) and diaze-
pam (N = 15) separately. The mean score 
for all 30 subjects in Group A is 18, and 18.6 
in Group M and 10.2 in Group D. Thus 
groups A and M exhibit a similar degree of 
anxiety which is greater than in group D 
but this difference is not statistically signi-
ficant. In Table 2, on the Hamilton depres-
sive scale this pattern is reversed, Groups M 
and D having high initial scores of 18.6 and 
18.0 respectively as compared to score of 10 
in the anxiety group. 
The improvement after drug treatment 
is given in terms of percentage reduction of 
scores at the end of 4 weeks treatment. The 
improvement after treatment with imi-
pramine is almost the same in all 3 groups 
being 62.5 %, 57.1 % and 73.4 % in Group A, 
M and D respectively. This suggests that 
imipramine reduces the anxiety level by ap-
proximately 2/3rd in all patients more so in 
the depressed group. Treatment with dia-
zepam also brings about similar degree of 
improvement, the figures being 70.4%, 
63.9%, and 60.9% for Groups A, M and D 
respectively. In this case the response is 
slightly better in the generalised anxiety 
group. An analysis of variance was carried 
out and yielded the following F values: 
a) Between drugs = 0.008 - Not significant 
b) Between groups = 0.329 - Not signific-
ant 
The improvement as measured by re-
duction of depression on the Hamilton De-
pressive Scale (Table 2) shows a slightly 
better response with imipramine in Group 
D (73.6%) somewhat less in Group M 
(66.5%) and least in Group A (48.8%). Ho-
wever the differences are not statistically 
significant, the reverse trend being evident 
on treatment with diazepam, the percen-
tage reduction being 58.5%, 56.3% and 
49.2 % in Groups A, M and D respectively, 
again suggesting a considerable degree of 
overlap in the three groups and drug ef-
fects. Analysis of variance gave the follow-
ing F values: 
a) Between drugs = 0.80 - Not significant 
b) Between groups = 0.01 - Not signific-
ant 
Table 3 shows the initial and final scores 
and percentage reduction of scores after 
treatment as measured on the Taylors ma-
nifest anxiety scale. The mean initial scores 
in all three groups is almost the same. The 
improvement on both imipramine and dia-
zepam treatment shows a better response in 
group A followed by group M and lesser in 
group D. Analysis of variance gave the fol-
lowing F values. 
a) Between drugs = 0.63 - Not significant 
b) Between groups = 10.60 - Significant at 
0.01 level. 
On the Amritsar Depressive Inventory 
(table 4) the initial scores are distinctly hig-
her in groups D and M as compared to 
group A (20.3, 19.9 and 9.0 respectively), 
this test thus clearly distinguishes the D and 
M groups as being in the depressed range 
while A group score is in the not depressed 
range. Furthermore, on treatment with 
imipramine group D shows the best im-
provement (74.1 %) as compared to M and 
A groups (63.8 and 38.6 % respectively). 
Analysis of variance gives the following va-
lues of F: 
A groups Analysis of variance gives the 
following values of F. 
a) Between drugs = 3.8 - Not significant 
b) Between groups = 9.98 - Significant at 
0.01 level. 
Table 5 shows the percentage improve-
ment in each symptom of the Hamilton GURMEET SINGH ET AL.  53 
Table 3 
Response to treatment with imipramine and diazepam as measured on Taylor manifest anxiety scale 
Imipramine Diazepam 
Initial Final Percent Initial Final Percent 
score score reduction score score reduction 
Group A 13.6 5.6 58.8 14.1 5.7 57.6 
Group M 16.6 7.4 57.2 17.10 9.0 44.7 
Group D 11.1 6.7 41.5 11.6 7.0 35.3 
Table 4 
Response to treatment with imipramine and diazepam as measured on Amritsar Depressive Inventory 
Imipramine Diazepam 
Initial Final Percent Initial Final Percent 
score score reduction score score reduction 
Group A 8.7 3.7 58.1 9.4 4.1 55.9 
Group M 18.8 6.8 63.8 21.0 10.3 50.9 
Group D 19.7 5.1 74.1 21.0 12.8 38.6 
Anxiety Scale after treatment with imi-
pramine and diazepam separately for the 
total sample. It is observed that there is a 
statistically significant (p<0.01) improve-
ment in the symptom of 'depressed mood' 
on treatment with imipramine as compared 
to diazepam, whereas imipramine in the 
symptom of'Fears' (p< 0.01). The overall 
improvement in the three groups on the 
two drugs was also evaluated by analysis of 
variance using a 2 x 3 design. The F ratio 
between drugs was found to be - 0.008 
(not significant) and for between patient 
groups was 0.239 (not significant). 
Table 6 shows the percentage improve-
ment in each symptom of the Hamilton 
Depression Scale. Since there were no pa-
tients with symptoms of loss of insight or 
loss of weight, these symptoms have not 
been included in the table. It is seen that 
imipramine is effective in improving the 
symptom of depression to the extent of 
66% in both the Anxiety and Depressive 
groups and to the extent of 55% in M 
group. Interestingly diazepam also is effec-
tive in reducing the level of depression by 
25% in the D group and 46% in the M 
group, but not effective in the Anxiety 
group. This difference is statistically signi-
ficant at 0.01 level. The only other symp-
tom in which imipramine is significantly 
better than diazepam is in the symptom of 
psychomotor retardation, and in relieving 
delayed insomnia especially in the de-
pressed group but it fails to reach statistical 
significance. On the other hand diazepam 
was more effective than imipramine in 
relieving the symptom of agitation in all 
three groups to the extent of 85, 80 and 50 
per cent in the three groups whereas imi-
pramine was effective to the extent of 
100 % in A group and 57 % in M group and 
no effect in D group. By using analysis of 
variance we get: 
a) between drugs F = 0.80 - Not significant 
b) between groups F = 0.01-Not signifi-
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Table 5 
Improvement in each symptom of Hamilton Anxiety Scale 
Imipramine Diazepam 
Symptom AMD Mean AMD Mean 
Anxious mood 
Tension 
Fears 
Insomnia 
Intellectual 
Depressed mood 
General somatic (muscular) 
General somatic (sensory) 
Cardiovascular 
Respiratory 
Gastrointenstinal 
Genitourinary 
Autonomic 
Behaviour at interview 
Mean 
61.1 
62.8 
50.0 
59.4 
75.0 
85.7 
38.9 
56.0 
77.3 
75.0 
61.1 
66.7 
36.8 
44.0 
63.4 
55.3 
59.4 
25.0 
60.0 
35.3 
65.0 
37.5 
68.7 
64.2 
71.4 
60.0 
57.1 
36.8 
39.0 
53.8 
66.7 
60.0 
0.0 
84.0 
78.6 
72.7 
66.6 
75.0 
' 83.3 
100.0 
57.1 
0.0 
71.4 
80.0 
71.2 
61.0 
60.7 
37.5 
67.8 
62.9 
74.5 
47.7 
66.6 
74.9 
82.1 
59.4 
41.3 
48.3 
54.3 
62.8 
72.5 
68.6 
100.0 
85.0 
100.0 
37.5 
66.7 
63.0 
68.0 
64.3 
68.7 
66.7 
65.2 
67.5 
68.6 
56.3 
60.0 
0.0 
77.1 
45.4 
51.7 
57.1 
65.1 
80.8 
83.3 
48.1 
75.0 
56.0 
76.0 
62.8 
56.3 
50.0 
60.7 
73.7 
42.8 
24.3 
54.5 
50.0 
100.0 
100.0 
71.4 
25.0 
80.0 
70.6 
55.3 
63.0 
59.5 
83.3 
73.6 
62.7 
37.8 
59.4 
59.4 
82.9 
82.9 
62.7 
55.6 
67.1 
71.4 
62.2 
Table 6 
Improvement in each symptom of Hamilton Depressive Scale 
Imipramine Diazepam 
Symptom AMD Mean AMD Mean 
Depression mood 
Depression guilt 
Depression suicide 
Insomnia (initial) 
Insomnia (middle) 
Insomnia (delayed) 
Work and interests 
Retardation 
Agitation 
Anxiety (psychic) 
Somatic symptoms 
Somatic symptoms 
Somatic symptoms 
Hypochondriasis 
Mean 
(G. 1) 
(Gen) 
(o.u) 
66.6 
0.0 
0.0 
64.8 
12.5 
60.0 
50.0 
50.0 
100.0 
60.7 
33.3 
61.9 
25.0 
50.0 
55.2 
55.2 
100.0 
55.6 
58.8 
100.0 
57.9 
57.9 
100.0 
57.1 
48.6 
72.7 
31.2 
50.0 
50.0 
58.8 
66.7 
57.1 
87.5 
70.0 
81.8 
84.6 
63.3 
85.7 
0.0 
67.8 
47.3 
70.8 
66.7 
75.0 
70.9 
62.0 
78.5 
47.7 
64.5 
64.8 
67.5 
57.1 
78.6 
52.4 
59.0 
51.1 
54.6 
47.2 
58.3 
61.6 
0.0 
100.0 
0.0 
66.7 
88.9 
66.7 
28.6 
0.0 
85.7 
70.0 
60.0 
53.8 
50.0 
50.0 
60.3 
47.7 
100.0 
54.3 
87.5 
73.1 
82.6 
51.8 
57.1 
80.0 
45.9 
52.3 
28.6 
20.0 
47.1 
54.8 
25.0 
100.0 
38.5 
83.3 
87.5 
50.0 
31.4 
40.0 
50.0 
43.7 
42.5 
28.1 
60.0 
100.0 
45.3 
23.7 
100.0 
31.0 
79.2 
83.2 
66.4 
37.3 
32.4 
71.9 
53.2 
51.6 
36.5 
43.3 
65.7 
56.3 GURMEET SINGH & R. K. SHARMA  55 
Discussion 
It is evident from Tables 1 and 3 which 
show the improvement on the Hamilton 
Anxiety Scale and the Taylor Manifest An-
xiety Scale respectively, that imipramine is 
as effective as diazepam in reduction of an-
xiety as measured on these two scales, Dia-
zepam being slightly more effective in the 
anxiety group and imipramine more effec-
tive in the depressive group with the mixed 
anxiety depressive group falling in bet-
ween. On the two depressive scales we find 
that imipramine is clearly more effec-
tive than Diazepam in reducing the level of 
depression as measured on the Hamilton 
Depression Scale in the depressive groups. 
Diazepam seems to be more effective in re-
ducing depression in the anxiety groups as 
compared to imipramine. 
It is thus apparent that contrary to ex-
pectations, there does not seem to be a clear 
cut difference in the pure anxiety group, 
the mixed anxiety depression group and the 
pure depression group in their selectiveness 
of response to either imipramine and diaze-
pam. Both drugs seem to be moderately ef-
fective in all groups, with antidepressants 
being slightly better in the depressed group 
and anxiolytics in the anxiety group. Our 
findings confirm the earlier reports of the 
efficiency of tricyclic antidepressants in the 
treatment of anxiety and that anxiety and 
depression are invariably both present even 
though the cases may be diagnosed as prim-
ary anxiety neurosis or depressive neurosis 
(Marks and Lader 1973, Clancey et al 1978, 
Hamilton 1980) and tends to support the 
suggestion of Akiskal (1984) that mixed an-
xiety depressions are the most common 
dysphoric mood state and that they respond 
well to tricyclic antidepressants. 
However, most earlier studies have ta-
ken anxiety states as a whole and have re-
ported that within this, panic anxiety only 
seems to respond to tricyclic antidepres-
sants which have been considered to be re-
latively ineffective in the treatment of ge-
neralised anxiety disorder (Tyrer 1973, 
Mountjoy and Roth 1977, and McNair and 
Kahn 1981). However, our findings clearly 
show that tricyclic antidepressants are also 
effective in the treatment of generalized 
anxiety disorder and almost as effective as 
diazepam. In none of the four rating scales 
used was there a significant difference in ef-
fectiveness between the two drugs. 
Considering individual symptoms the 
only two symptoms in which imipramine 
was found to be significantly more effec-
tive than diazepam were 'Depressed Mood' 
and 'Psychomotor retardation', while diaze-
pam was significantly more effective as 
compared to imipramine in the symptom of 
'Fears'. None of the other symptoms were 
discriminatory. In fact the mean overall 
percentage improvement on imipramine 
Vs diazepam as measured on the Hamilton 
Anxiety Scale was found to be 62.8% and 
62.2% respectively, whereas on the Hamil-
ton Depressive Scale the overall percentage 
improvement on imipramine Vs diazepam 
was 61.3 % and 56.5 % respectively. The fin-
dings of the present study thus establish the 
effectiveness of tricyclic antidepressants in 
the treatment of generalized anxiety disor-
der and at the same time cast doubt on the 
validity of the clinical differentiation of an-
xiety neurosis and depressive neurosis both 
phenomenologically and from the point of 
view of predicting treatment response, the 
mixed-anxious depressive group appears 
closer to the 'anxiety' group on scales that 
measure anxiety, and on the other hand are 
closer to the 'depressive' group on scales 
that measure depression and hence clinical-
ly would be liable to be arbitrarily assigned 
either of the two diagnosis depending on 
the whims of the investigator and since thev 
constitute a large percentage of patients diag-
nosed as anxiety or depressive neurosis, this 
highlights the inadequacy of the existing sys-
tem of classification in this area. 56  ANXIETY AND DEPRESSIVE NEUROSIS 
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